James Coggan, DO
Hematology & Oncology · San Diego, CANPI 1508246042
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Tempus AI, Inc at 53.7% of the total. 2025 is the largest year on record at $56, 2.4 times the $23 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 4 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tempus AI, Inc$56
- Bristol Myers Squibb$25
- Deciphera Pharmaceuticals Inc.$23
Across 11 payments — averaging $10,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$71K
- AstraZeneca$27K
- Pfizer$21K
- Bristol Myers Squibb$1K
- E.r. Squibb & Sons, L.L.C.$798
What the payments were for
- Food & beverage$104100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tempus AI, Inc | 2 | $56 |
| Bristol Myers Squibb | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
How this compares
$104 in reported general payments places this provider in the 10th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 26 | $392,104 |
| TruqapCapivasertib | 11 | $245,090 |
| TagrissoOsimertinib Mesylate | 11 | $185,969 |
| XareltoRivaroxaban | 14 | $11,475 |
| EliquisApixaban | 17 | $10,305 |
| Abiraterone Acetate | 15 | $3,846 |
| Imatinib Mesylate | 11 | $2,019 |
| Exemestane | 12 | $872 |
| Mirtazapine | 20 | $504 |
| Prochlorperazine Maleate | 29 | $502 |
| Ondansetron OdtOndansetron | 21 | $498 |
| Dexamethasone | 29 | $230 |
| Acyclovir | 34 | $222 |
| Prednisone | 36 | $202 |
| Anastrozole | 15 | $180 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in San Diego
- Wendy LevinSan Diego$760K
- Rana McKaySan Diego$530K
- Ezra CohenSan Diego$495K
- Annette von DrygalskiSan Diego$406K
- Lyudmila BazhenovaSan Diego$328K
- Sandip PatelSan Diego$295K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.